Trades on 1 secondary market

Novamab

Novamab (洛启生物) is a Shanghai-based clinical-stage biopharmaceutical company specializing in VHH (nanobody) antibody drug development for respiratory and inflammatory diseases such as asthma, COPD, and IBD. Its platforms span inhaled antibodies, oral antibodies, and dual/multi-specific antibodies alo

minimal 5.7 / 100 0 APIs View provider profile →
CompanyBiotechnologyPharmaceuticalBiopharmaceuticalAntibodyNanobody

Novamab is an API provider whose private shares are listed on 1 secondary market: EquityZen.

Where It Trades

EZ EquityZen View listing →

Listing data is compiled from the public marketplace pages of Forge Global, Hiive, EquityZen, Nasdaq Private Market, and Augment. A listing indicates that a venue has published a page for this company — it is not an offer, a quote, or investment advice, and APIs.io has no affiliation with any venue.